Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 11/20 | 0.42 |
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2260437 | 0.90 | CRHR1 (0.43) | CRHR1DPP4HSD11B1DPP8 | |
| SCHEMBL1924207 | 0.84 | DPP4 (0.50) | CRHR1DPP4HSD11B1ALDH1A1HPGD | |
| SCHEMBL2255752 | 0.81 | HSD11B1 (0.40) | CRHR1DPP4HSD11B1ALDH1A1HPGD | |
| SCHEMBL2255303 | 0.80 | DPP4 (0.41) | CRHR1DPP4HSD11B1ALDH1A1HPGD | |
| SCHEMBL2256465 | 0.79 | PTGS1 (0.41) | CRHR1DPP4HSD11B1ALDH1A1HPGD | |
| SCHEMBL2254961 | 0.78 | HSD11B1 (0.40) | CRHR1DPP4HSD11B1ALDH1A1HPGD | |
| SCHEMBL1922413 | 0.77 | DPP4 (0.49) | CRHR1DPP4NPC1DPP8 | |
| SCHEMBL2260849 | 0.74 | DPP4 (0.41) | CRHR1DPP4DPP8 | |
| SCHEMBL2255880 | 0.74 | CRHR1 (0.40) | CRHR1DPP4HSD11B1DPP8KMT2A | |
| SCHEMBL2255239 | 0.74 | CRHR1 (0.41) | CRHR1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| US-7994203-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2328902-A1 | PYRAZOLO [5,1-B]OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | Novartis AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010015628-A1 | PYRAZOLO [5,1-B] OXAZOLE DERIVATIVES AS CRF1 ANTAGONISTS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-20100035874-A1 | Organic compounds | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035874-A1 | Organic compounds | CRH, CRHR1, CRHR2 | CRHR1 2/4885DPP4 958/4885HSD11B1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.